Overall, the unexpected role for PME‐1 in CRCs is intriguing and calls for careful examination of cancer‐specific function for each of the PP2A inhibitor proteins when considering their role as biomarkers and potential targets for future cancer therapies. This evidence concerns the gene PTPA and cancer.